舒泰神跌2.10%，成交额6771.24万元，主力资金净流出213.24万元

Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of biological products and some chemical drugs, with a significant revenue contribution from injectable nerve growth factor (Sutai) at 59.17% and compound polyethylene glycol electrolyte powder at 33.19% [1][2] Stock Performance - As of September 29, Shuyou Shen's stock price decreased by 2.10% to 33.16 CNY per share, with a total market capitalization of 15.843 billion CNY [1] - The stock has seen a year-to-date increase of 347.50%, but has declined by 8.68% over the last five trading days, 38.43% over the last 20 days, and 24.84% over the last 60 days [1] Financial Performance - For the first half of 2025, Shuyou Shen reported a revenue of 126 million CNY, a year-on-year decrease of 31.14%, and a net profit attributable to shareholders of -24.636 million CNY, a decline of 619.70% [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 29.20% to 31,700, with an average of 14,327 shares per shareholder, down by 22.60% [2] - The company has cumulatively distributed 771 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Institutional Holdings - Notable new institutional shareholders include Xingquan He Run Mixed A, holding 15.721 million shares, and several other funds, indicating a shift in shareholder composition [3]